Topics

FDA Grants Priority Review for Kite’s BLA for KTE-X19 for Treatment of Relapsed or Refractory Mantle Cell Lymphoma

16:37 EST 11 Feb 2020 | Speciality Pharma Journal

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma …

Original Article: FDA Grants Priority Review for Kite’s BLA for KTE-X19 for Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review for Kite’s BLA for KTE-X19 for Treatment of Relapsed or Refractory Mantle Cell Lymphoma"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...